288 related articles for article (PubMed ID: 30964958)
1. Small molecule targeting of RNA structures in neurological disorders.
Angelbello AJ; Chen JL; Disney MD
Ann N Y Acad Sci; 2020 Jul; 1471(1):57-71. PubMed ID: 30964958
[TBL] [Abstract][Full Text] [Related]
2. Nucleic Acid-Targeted Small Molecules have Therapeutic Potential in the Treatment of Spinal Muscular Atrophy: Small-molecule drugs that can selectively bind RNA and modulate pre-mRNA splicing have potential as a treatment strategy for human disease, including spinal muscular atrophy.
Am J Med Genet A; 2018 Aug; 176(8):1698-1699. PubMed ID: 30136439
[No Abstract] [Full Text] [Related]
3. Repeat RNA expansion disorders of the nervous system: post-transcriptional mechanisms and therapeutic strategies.
Schwartz JL; Jones KL; Yeo GW
Crit Rev Biochem Mol Biol; 2021 Feb; 56(1):31-53. PubMed ID: 33172304
[TBL] [Abstract][Full Text] [Related]
4. Identifying and validating small molecules interacting with RNA (SMIRNAs).
Disney MD; Velagapudi SP; Li Y; Costales MG; Childs-Disney JL
Methods Enzymol; 2019; 623():45-66. PubMed ID: 31239057
[TBL] [Abstract][Full Text] [Related]
5. G-quadruplex-binding small molecules ameliorate
Simone R; Balendra R; Moens TG; Preza E; Wilson KM; Heslegrave A; Woodling NS; Niccoli T; Gilbert-Jaramillo J; Abdelkarim S; Clayton EL; Clarke M; Konrad MT; Nicoll AJ; Mitchell JS; Calvo A; Chio A; Houlden H; Polke JM; Ismail MA; Stephens CE; Vo T; Farahat AA; Wilson WD; Boykin DW; Zetterberg H; Partridge L; Wray S; Parkinson G; Neidle S; Patani R; Fratta P; Isaacs AM
EMBO Mol Med; 2018 Jan; 10(1):22-31. PubMed ID: 29113975
[TBL] [Abstract][Full Text] [Related]
6. Discovery of a potent small molecule inhibiting Huntington's disease (HD) pathogenesis via targeting CAG repeats RNA and Poly Q protein.
Khan E; Mishra SK; Mishra R; Mishra A; Kumar A
Sci Rep; 2019 Nov; 9(1):16872. PubMed ID: 31728006
[TBL] [Abstract][Full Text] [Related]
7. RNA Structures as Mediators of Neurological Diseases and as Drug Targets.
Bernat V; Disney MD
Neuron; 2015 Jul; 87(1):28-46. PubMed ID: 26139368
[TBL] [Abstract][Full Text] [Related]
8. Antisense therapies for movement disorders.
Scoles DR; Pulst SM
Mov Disord; 2019 Aug; 34(8):1112-1119. PubMed ID: 31283857
[TBL] [Abstract][Full Text] [Related]
9. Exploring the Potential of Small Molecule-Based Therapeutic Approaches for Targeting Trinucleotide Repeat Disorders.
Verma AK; Khan E; Bhagwat SR; Kumar A
Mol Neurobiol; 2020 Jan; 57(1):566-584. PubMed ID: 31399954
[TBL] [Abstract][Full Text] [Related]
10. Comparison of small molecules and oligonucleotides that target a toxic, non-coding RNA.
Costales MG; Rzuczek SG; Disney MD
Bioorg Med Chem Lett; 2016 Jun; 26(11):2605-9. PubMed ID: 27117425
[TBL] [Abstract][Full Text] [Related]
11. Antisense therapies in neurological diseases.
Brunet de Courssou JB; Durr A; Adams D; Corvol JC; Mariani LL
Brain; 2022 Apr; 145(3):816-831. PubMed ID: 35286370
[TBL] [Abstract][Full Text] [Related]
12. Targeted Oligonucleotides for Treating Neurodegenerative Tandem Repeat Diseases.
Zain R; Smith CIE
Neurotherapeutics; 2019 Apr; 16(2):248-262. PubMed ID: 31098852
[TBL] [Abstract][Full Text] [Related]
13. Emerging small-molecule therapeutic approaches for amyotrophic lateral sclerosis and frontotemporal dementia.
Brown DG; Shorter J; Wobst HJ
Bioorg Med Chem Lett; 2020 Feb; 30(4):126942. PubMed ID: 31926785
[TBL] [Abstract][Full Text] [Related]
14. Myricetin Reduces Toxic Level of CAG Repeats RNA in Huntington's Disease (HD) and Spino Cerebellar Ataxia (SCAs).
Khan E; Tawani A; Mishra SK; Verma AK; Upadhyay A; Kumar M; Sandhir R; Mishra A; Kumar A
ACS Chem Biol; 2018 Jan; 13(1):180-188. PubMed ID: 29172480
[TBL] [Abstract][Full Text] [Related]
15. Molecular genetic advances in neurodegenerative disorders.
Aguilera AJ
Clin Lab Med; 1995 Dec; 15(4):915-26. PubMed ID: 8838230
[TBL] [Abstract][Full Text] [Related]
16. Induction and reversal of myotonic dystrophy type 1 pre-mRNA splicing defects by small molecules.
Childs-Disney JL; Stepniak-Konieczna E; Tran T; Yildirim I; Park H; Chen CZ; Hoskins J; Southall N; Marugan JJ; Patnaik S; Zheng W; Austin CP; Schatz GC; Sobczak K; Thornton CA; Disney MD
Nat Commun; 2013; 4():2044. PubMed ID: 23806903
[TBL] [Abstract][Full Text] [Related]
17. Small molecule splicing modifiers with systemic HTT-lowering activity.
Bhattacharyya A; Trotta CR; Narasimhan J; Wiedinger KJ; Li W; Effenberger KA; Woll MG; Jani MB; Risher N; Yeh S; Cheng Y; Sydorenko N; Moon YC; Karp GM; Weetall M; Dakka A; Gabbeta V; Naryshkin NA; Graci JD; Tripodi T; Southwell A; Hayden M; Colacino JM; Peltz SW
Nat Commun; 2021 Dec; 12(1):7299. PubMed ID: 34911927
[TBL] [Abstract][Full Text] [Related]
18. Recent Advances in the Treatment of Huntington's Disease: Targeting DNA and RNA.
Shannon KM
CNS Drugs; 2020 Mar; 34(3):219-228. PubMed ID: 31933283
[TBL] [Abstract][Full Text] [Related]
19. The disease-associated r(GGGGCC)n repeat from the C9orf72 gene forms tract length-dependent uni- and multimolecular RNA G-quadruplex structures.
Reddy K; Zamiri B; Stanley SYR; Macgregor RB; Pearson CE
J Biol Chem; 2013 Apr; 288(14):9860-9866. PubMed ID: 23423380
[TBL] [Abstract][Full Text] [Related]
20. SMMDB: a web-accessible database for small molecule modulators and their targets involved in neurological diseases.
Mishra SK; Jain N; Shankar U; Tawani A; Mishra A; Kumar A
Database (Oxford); 2018 Jan; 2018():1-12. PubMed ID: 30219840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
